… anticoagulants included enoxaparin (1 mg/kg twice daily), apixaban (≥ 5 mg twice daily),
unfractionated heparin … provided mortality benefit to ICU patients with critical COVID-19 disease…

… the use of heparin products as the anticoagulant of choice in … from multiple anticoagulants
(enoxaparin to apixaban to … cause substantial morbidity and mortality. This patient experienced …

… heparin (LMWH) and UFH doses in non-COVID-19 patients. … of enoxaparin compared with
27% of 22 COVID-19 patients … Our ICU mortality was similar among groups based on anti-…

… (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2),
has besieged the world with its high morbidity and mortality … either different anticoagulation …

… therapy or subcutaneous low-molecular weight heparin (enoxaparin) … to ensure strict
compliance with anticoagulant therapy. … No mortality cases related to massive pulmonary …

… Danish national guidelines recommended dosages: apixaban and dabigatranetexilat – two
tablets a … the possible benefit of other anticoagulants such as heparins in COVID-19 patients. …

… The efficacy of low-molecular-weight heparin (LMWH) doses … risk of mortality in patients
with the severe form of COVID-19 [… and Apixaban) in four out of five hospitalized COVID-19 …

… cases and over 2,500,000 deaths.Recent observations … Enoxaparin was the first low
molecular weight heparin to be … findings of anticoagulation dosing regimens in COVID-19 but …

… with a significant reduction in mortality among patients with COVID-19 [23]. Yuan … heparin
(UFH) and newer direct oral anticoagulants (DOACs) (ie betrixaban, rivaroxaban and apixaban…

… (eg, renal function, history of heparin-induced thrombocytopenia, concerns … impact. As of
28 October 2020, over 44 million cases and 1.1 million deaths had been attributed to COVID-19…